SG11201702628XA - Boronic acid derivatives - Google Patents
Boronic acid derivativesInfo
- Publication number
- SG11201702628XA SG11201702628XA SG11201702628XA SG11201702628XA SG11201702628XA SG 11201702628X A SG11201702628X A SG 11201702628XA SG 11201702628X A SG11201702628X A SG 11201702628XA SG 11201702628X A SG11201702628X A SG 11201702628XA SG 11201702628X A SG11201702628X A SG 11201702628XA
- Authority
- SG
- Singapore
- Prior art keywords
- acid derivatives
- boronic acid
- boronic
- derivatives
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14003389 | 2014-10-01 | ||
| PCT/EP2015/001973 WO2016050358A1 (en) | 2014-10-01 | 2015-10-01 | Boronic acid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201702628XA true SG11201702628XA (en) | 2017-04-27 |
Family
ID=51751859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702628XA SG11201702628XA (en) | 2014-10-01 | 2015-10-01 | Boronic acid derivatives |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10669289B2 (en) |
| EP (1) | EP3201206B1 (en) |
| JP (1) | JP6662865B2 (en) |
| KR (1) | KR102457840B1 (en) |
| CN (1) | CN107001391B (en) |
| AU (1) | AU2015327345B9 (en) |
| BR (1) | BR112017006622A2 (en) |
| CA (1) | CA2963203A1 (en) |
| CL (1) | CL2017000792A1 (en) |
| DK (1) | DK3201206T3 (en) |
| ES (1) | ES2761774T3 (en) |
| IL (1) | IL251302B (en) |
| MX (1) | MX2017003999A (en) |
| MY (1) | MY186911A (en) |
| NZ (1) | NZ730981A (en) |
| PH (1) | PH12017500293A1 (en) |
| RU (1) | RU2717558C2 (en) |
| SG (1) | SG11201702628XA (en) |
| UA (1) | UA122672C2 (en) |
| WO (1) | WO2016050358A1 (en) |
| ZA (1) | ZA201703007B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| RU2017115193A (en) | 2014-10-01 | 2018-11-06 | Мерк Патент Гмбх | Derivatives of Boronic Acid |
| MX2017004043A (en) | 2014-10-01 | 2017-07-04 | Merck Patent Gmbh | Boronic acid derivatives. |
| RU2017115188A (en) | 2014-10-01 | 2018-11-06 | Мерк Патент Гмбх | Derivatives of Boronic Acid |
| AU2018210839B2 (en) * | 2017-01-18 | 2022-01-20 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
| ES2927283T3 (en) | 2017-08-24 | 2022-11-03 | Merck Patent Gmbh | Boronic acid derivatives |
| TW201912624A (en) * | 2017-08-29 | 2019-04-01 | 大陸商浙江海正藥業股份有限公司 | (E)-α,β-unsaturated guanamine compound, preparation method and use thereof |
| EP3694528A4 (en) * | 2017-10-13 | 2021-07-28 | The Regents of the University of California | Mtorc1 modulators |
| SG11202003867SA (en) * | 2017-11-16 | 2020-05-28 | Principia Biopharma Inc | Immunoproteasome inhibitors |
| DK3710457T3 (en) * | 2017-11-16 | 2022-10-24 | Principia Biopharma Inc | IMMUNOPROTEASE INHIBITORS |
| CN112469480A (en) | 2018-07-26 | 2021-03-09 | 默克专利股份公司 | Boronic acid derivatives |
| CN113135944A (en) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | Boronic acid derivatives |
| CN113135943A (en) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | Boronic acid derivatives |
| AU2022318343A1 (en) | 2021-07-29 | 2024-03-14 | Merck Patent Gmbh | Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain |
| WO2023061445A1 (en) * | 2021-10-14 | 2023-04-20 | 首药控股(北京)股份有限公司 | Boronic acid derivative |
| WO2023232830A1 (en) | 2022-06-02 | 2023-12-07 | Merck Patent Gmbh | Boronic acid adducts |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5658885A (en) * | 1993-04-27 | 1997-08-19 | The Dupont Merck Pharmaceutical Company | Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes |
| US5462964A (en) * | 1993-10-20 | 1995-10-31 | The Du Pont Merck Pharmaceutical Company | Dipeptide boronic acid inhibitors of trypsin-like enzymes |
| IL111175A0 (en) | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
| WO2001002424A2 (en) * | 1999-07-07 | 2001-01-11 | Du Pont Pharmaceuticals Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
| WO2004022071A1 (en) * | 2002-09-09 | 2004-03-18 | Trigen Limited | Multivalent metal salts of boronic acids for treating thrombosis |
| US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| UA88771C2 (en) * | 2003-08-14 | 2009-11-25 | Сефалон, Инк. | Proteasome inhibitors and methods of using the same (variants) |
| AR075090A1 (en) * | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM. |
| RU2586219C2 (en) * | 2010-04-22 | 2016-06-10 | Марс, Инкорпорейтед | Arginase inhibitors and therapeutic use thereof |
| EP2793900B1 (en) * | 2011-12-22 | 2018-08-22 | Ares Trading S.A. | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
| NZ723762A (en) | 2014-01-31 | 2023-03-31 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2’ groups as factor xia inhibitors |
| NO2721243T3 (en) | 2014-10-01 | 2018-10-20 | ||
| BR112017006708A2 (en) | 2014-10-01 | 2017-12-26 | Janssen Pharmaceuticals Inc | mono- or disubstituted indoles as inhibitors of dengue viral replication |
| SG11201702463YA (en) | 2014-10-01 | 2017-04-27 | Janssen Pharmaceuticals Inc | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| RU2017115188A (en) | 2014-10-01 | 2018-11-06 | Мерк Патент Гмбх | Derivatives of Boronic Acid |
| RU2017115193A (en) | 2014-10-01 | 2018-11-06 | Мерк Патент Гмбх | Derivatives of Boronic Acid |
| MX2017004043A (en) | 2014-10-01 | 2017-07-04 | Merck Patent Gmbh | Boronic acid derivatives. |
-
2015
- 2015-10-01 MX MX2017003999A patent/MX2017003999A/en active IP Right Grant
- 2015-10-01 NZ NZ730981A patent/NZ730981A/en unknown
- 2015-10-01 JP JP2017518070A patent/JP6662865B2/en active Active
- 2015-10-01 SG SG11201702628XA patent/SG11201702628XA/en unknown
- 2015-10-01 EP EP15778613.8A patent/EP3201206B1/en active Active
- 2015-10-01 RU RU2017115192A patent/RU2717558C2/en active
- 2015-10-01 UA UAA201704168A patent/UA122672C2/en unknown
- 2015-10-01 ES ES15778613T patent/ES2761774T3/en active Active
- 2015-10-01 KR KR1020177011562A patent/KR102457840B1/en active IP Right Grant
- 2015-10-01 MY MYPI2017701058A patent/MY186911A/en unknown
- 2015-10-01 AU AU2015327345A patent/AU2015327345B9/en active Active
- 2015-10-01 DK DK15778613.8T patent/DK3201206T3/en active
- 2015-10-01 US US15/516,427 patent/US10669289B2/en active Active
- 2015-10-01 CN CN201580053501.9A patent/CN107001391B/en active Active
- 2015-10-01 BR BR112017006622-0A patent/BR112017006622A2/en not_active Application Discontinuation
- 2015-10-01 CA CA2963203A patent/CA2963203A1/en active Pending
- 2015-10-01 WO PCT/EP2015/001973 patent/WO2016050358A1/en active Application Filing
-
2017
- 2017-02-16 PH PH12017500293A patent/PH12017500293A1/en unknown
- 2017-03-21 IL IL251302A patent/IL251302B/en active IP Right Grant
- 2017-03-31 CL CL2017000792A patent/CL2017000792A1/en unknown
- 2017-04-28 ZA ZA2017/03007A patent/ZA201703007B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107001391B (en) | 2020-11-27 |
| BR112017006622A2 (en) | 2018-07-03 |
| CL2017000792A1 (en) | 2017-11-10 |
| US20180179232A1 (en) | 2018-06-28 |
| MX2017003999A (en) | 2018-02-09 |
| ES2761774T3 (en) | 2020-05-21 |
| CA2963203A1 (en) | 2016-04-07 |
| CN107001391A (en) | 2017-08-01 |
| EP3201206B1 (en) | 2019-09-18 |
| WO2016050358A1 (en) | 2016-04-07 |
| IL251302B (en) | 2020-03-31 |
| ZA201703007B (en) | 2022-05-25 |
| AU2015327345B9 (en) | 2020-06-18 |
| KR102457840B1 (en) | 2022-10-21 |
| RU2717558C2 (en) | 2020-03-24 |
| UA122672C2 (en) | 2020-12-28 |
| JP6662865B2 (en) | 2020-03-11 |
| AU2015327345B2 (en) | 2019-12-05 |
| NZ730981A (en) | 2024-01-26 |
| MY186911A (en) | 2021-08-26 |
| EP3201206A1 (en) | 2017-08-09 |
| RU2017115192A (en) | 2018-11-06 |
| IL251302A0 (en) | 2017-05-29 |
| DK3201206T3 (en) | 2019-12-16 |
| KR20170067802A (en) | 2017-06-16 |
| AU2015327345A1 (en) | 2017-05-18 |
| RU2017115192A3 (en) | 2019-03-26 |
| US10669289B2 (en) | 2020-06-02 |
| JP2017531646A (en) | 2017-10-26 |
| PH12017500293A1 (en) | 2017-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201703007B (en) | Boronic acid derivatives | |
| GB201419865D0 (en) | Solution | |
| GB201517022D0 (en) | No details | |
| SG11201702620SA (en) | Boronic acid derivatives | |
| GB201410907D0 (en) | No details | |
| SG11201702625PA (en) | Boronic acid derivatives | |
| GB201517404D0 (en) | No details | |
| SG11201702623TA (en) | Boronic acid derivatives | |
| GB201418217D0 (en) | No details | |
| GB201418216D0 (en) | No details | |
| SG11201609205WA (en) | Heterocyclyl-butanamide derivatives | |
| PL3131898T3 (en) | Fluoroalkylfluorene derivatives | |
| GB201517412D0 (en) | No details | |
| GB201516796D0 (en) | No details | |
| IL248773A0 (en) | Naphthyridinedione derivatives | |
| PL3672977T3 (en) | Boronic acid derivatives | |
| GB201517574D0 (en) | No details | |
| DK3200779T3 (en) | Novel anthranilic acid derivatives | |
| PL3418273T3 (en) | Flavagline derivatives | |
| PT3097076T (en) | Novel cyp-eicosanoid derivatives | |
| IL248629B (en) | Cycloalkyl-linked diheterocycle derivatives | |
| PL3119744T3 (en) | 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives | |
| GB201410910D0 (en) | No details | |
| GB201417986D0 (en) | No details | |
| GB201407585D0 (en) | SMA-Inter Act |